Ilomedin (Iloprost Trometamol)

Iloprost trometamol mimics the natural prostacyclin (PGI2) by binding to IP receptors on vascular smooth‑muscle cells. This activation raises cyclic AMP levels, causing smooth‑muscle relaxation, vasodilation, inhibition of platelet aggregation, and antiproliferative effects, which together improve circulation in affected vessels.

The dosing regimen for Ilomedin is individualized by the prescribing clinician based on the specific indication, patient condition, and response to therapy. Healthcare professionals determine the infusion rate, concentration, and duration according to established clinical guidelines and patient monitoring.

Safety data for Ilomedin in pregnancy and lactation are limited. It should only be used if the potential benefits justify the potential risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Ilomedin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Ilomedin (iloprost) is a synthetic prostacyclin analog administered intravenously, offering rapid onset and short half‑life compared with longer‑acting agents such as epoprostenol or treprostinil. Its dosing flexibility allows titration to effect, but it requires continuous infusion and careful monitoring, whereas some alternatives are available for subcutaneous or inhaled routes.

Ilomedin should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Ilomedin is supplied as a sterile intravenous solution and is administered by continuous infusion through a dedicated IV line. The infusion rate is set by the prescriber and adjusted based on clinical response and tolerability, with regular monitoring of vital signs during treatment.

The most serious risks include severe hypotension, pulmonary edema, significant bleeding, thrombocytopenia, and rare anaphylactic reactions. Patients should be closely monitored for sudden drops in blood pressure, respiratory distress, bleeding signs, or allergic symptoms, and treatment should be stopped if any serious adverse event occurs.

Ilomedin is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, those with active uncontrolled bleeding, severe hypotension, or in whom vasodilation could be hazardous. Caution is also advised for individuals with severe hepatic or renal impairment, and it should be avoided during pregnancy unless absolutely necessary.